Interactions between ionizing radiation and drugs in head and neck cancer: How can we maximize the therapeutic index?

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 807-811

  Harrington, Kevin J ^a,b   Nutting, Christopher M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTIBODY CONJUGATE; BIOREDUCTIVE DRUG; CARBOGEN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DRUG VEHICLE; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; GEFITINIB; GEMCITABINE; IMC C 225; IRINOTECAN; LIPOSOME; MITOMYCIN C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ICR 62; NICOTINAMIDE; NITROIMIDAZOLE; PACLITAXEL; PANITUMUMAB; POLYMER; RECOMBINANT ERYTHROPOIETIN; SEMAXANIB; TAXANE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CELL HYPOXIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NOTE; PROBABILITY; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIATION RESPONSE; RADIOLOGICAL PARAMETERS; RADIOSENSITIZATION; RECEPTOR BLOCKING; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; THERAPY RESISTANCE; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION, IONIZING;

EID: 0036591185     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (57)

1. Munro AJ: Head and neck cancer. In: Treatment of Cancer, 3rd Edition. Price P, Sikora K (Eds), Chapman and Hall, London, UK (1995):271-355.
2. Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK: The tumor volume and clonogen number relationship: Tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys (1995) 33(2):281-287.
3. O-Charoenrat P, Rhys-Evans PH, Eccles SA: Expression of matrix metallproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg (2001) 127(7):813-820.
4. O-Charoenrat P, Rhys-Evans P, Eccles SA: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer (2001) 92(3):556-568.
5. O-Charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA: Epidermial growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res (2000) 60(4):1121-1128.
6. Brown JM: The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res (1999) 59(23):5863-5870.
7. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol (1996) 6(1):10-21.
8. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol (1996) 41(1):31-39.
9. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely effects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1997) 38(2):285-289.
10. Nutting CM, Rowbottom CG, Cosgrove VP, Henk JM, Dearnaley DP, Robinson MH, Conway J, Webb S: Optimisation of radiotherapy for carcinoma of the parotid gland: A comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother Oncol (2001) 60(2):163-172.
11. Adams EJ, Nutting CM, Convery DJ, Cosgrove VP, Henk JM, Dearnaley DP, Webb S: Potential role of intensity-modulated radiotherapy in the treatment of tumors of the maxillary sinus. Int J Radiat Oncol Biol Phys (2001) 51(3):579-588.
12. Mendenhall WM, Amdur RJ, Siemann DW, Parsons JT: Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck. Curr Opin Oncol (2000) 12(3):207-214.
13. McMillan TJ: In: Treatment of Cancer, 3rd Edition. Price P, Sikora K (Eds), Chapman and Hall, London, UK (1995):43-56.
14. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 48(1):7-16.
15. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys (1979) 5(1):85-91.
16. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer (1995) 71(1):83-91.
17. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet (2000) 355(9208):949-955.
18. Hennequin C, Favoudon V: Biological basis for chemo-radiotherapy interactions. Eur J Cancer (2002) 38(2):223-230.
19. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE: Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol (2001) 19(7):1961-1969.
20. Rosenthal DI, Lee JH, Sinard R, Yardley DA, Machtay M, Rosen DM, Egorin MJ, Weber RS, Weinstein GS, Chalian AA, Miller LK, Frenkel EP, Carbone DP: Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol (2001) 19(5):1363-1373.
21. Koukourakis MI, Bizakis JG, Skoulakis CE, Kyrmizakis D, Giatromanolaki A, Papadakis CE, Prokopakis E, Amanakis Z, Hellidonis ES: Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res (1999) 19(3B):2305-2309.
22. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS: Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol (2001) 19(3):792-799.
23. Benasso M, Merlano M, Sanguineti G, Corvo R, Numico G, Ricci I, Pallestrini E, Santelli A, Vitale V, Marchetti G, Rosso R: Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: A feasibility study. Am J Clin Oncol (2001) 24(6):618-622.
24. Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol (1996) 14(12):3156-3174.
25. Henk JM: Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: Overview of radiation morbidity. Clin Oncol (R Coll Radiol) (1997) 9(5):308-312.
26. Henk JM: Concomitant chemoradiation for head and neck cancer: Saving lives or Grays? Clin Oncol (R Coll Radiol) (2001) 13(5):333-335.
27. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol (1998) 46(2):135-146.
28. Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys (1998) 42(4):803-806.
29. Pradier O, Eberlein K, Weiss E, Jackel MC, Hess CF: Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer. Br J Radiol (2001) 74(880):368-374.
30. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, Von Roemeling R: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 19(2):535-542.
31. Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH: Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol (2002) 29(1 Suppl 4):102-109.
32. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, Stratford IJ: Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent. Br J Cancer (2000) 82(12):1984-1990.
33. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer (2001) 85(4):625-629.
34. Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S: An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther (1999) 6(10):1721-1727.
35. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S: Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res (2000) 60(11):2936-2941.
36. Harrington KJ: Liposomal cancer chemotherapy: Current clinical applications and future prospects. Exp Opin Investig Drugs (2001) 10(6):1045-1061.
37. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 7(2):243-254.
38. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS: Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer (2001) 37(16):2015-2022.
39. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Helidonis ES: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol (1999) 17(11):3512-3521.
40. Lango MN, Shin DM, Grandis JR: Targeting growth factor receptors: Integration of novel therapeutic in the management of head and neck cancer. Curr Opin Oncol (2001) 13(3):168-175.
41. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer (2002) 94(5):1593-1611.
42. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 19(13):3234-3243.
43. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M: Phase I trial and tumor localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer (1996) 73(2):228-235.
44. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G: Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer (2002) 86(5):819-827.
45. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys (1998) 42(4):899-903.
46. Landuyt W, Ahmed B, Nuyts S, Theys J, Op De Beeck M, Rijnders A, Anne J, Van Oosterom A, Van Den Bogaert W, Lambin P: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys (20001) 49(2):443-450.
47. Murata R, Overgaard J, Horsman MR: Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys (2001) 51(4):1018-1024.
48. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res (2001) 61(12):4716-4722.
49. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394(6690):287-291.
50. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res (1998) 58(24):5686-5689.
51. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J (2000) 6(5):287-293.
52. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res (2001) 61(6):2413-2419.
53. Ning S, Laird D, Cherrington JM, Knox SJ: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res (2002) 157(1):45-51.
54. Lee CG, Heijn M, Di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 60(19):5565-5570.
55. Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E: Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys (2001) 51(4):1008-1017.
56. Stackhouse MA, Pederson LC, Grizzle WE, Curiel DT, Gebert J, Haack K, Vickers SM, Mayo MS, Buchsbaum DJ: Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther (2000) 7(12):1019-1026.
57. Marples B, Greco O, Joiner MC, Scott SD: Molecular approaches to chemo-radiotherapy. Eur J Cancer (2002) 38(2):231-239.